Blue Arrow Capital Management’s Novartis NVS Stock Holding History

Blue Arrow Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-27,201	Closed	-$2.4M	–	168
2015 Q1	$2.4M	Buy	+27,201	New	+$2.41M	0.23%	99
2014 Q4	–	Sell	-3,348	Closed	-$282K	–	224
2014 Q3	$282K	Buy	+3,348	New	+$271K	0.03%	171

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Blue Arrow Capital Management's NVS Position: Q2 2015 in Review

Blue Arrow Capital Management sold out of Novartis (NVS) in Q2 2015, closing a stake of 27,201 shares — an estimated $2.4M sold.

Blue Arrow Capital Management first reported a position in NVS in Q3 2014 and held it in 2 quarters. The position peaked at $2.4M in Q1 2015. 945 funds tracked by Wall St. Rank hold NVS as of Q2 2015.

Blue Arrow Capital Management reported no remaining Novartis position as of Q2 2015 after selling out during the quarter.
Blue Arrow Capital Management sold 27,201 Novartis shares in Q2 2015, an estimated $2.4M.
Blue Arrow Capital Management first reported a position in Novartis in Q3 2014 and held it in 2 quarters.
Blue Arrow Capital Management's Novartis position peaked at $2.4M in Q1 2015.
945 funds tracked by Wall St. Rank held Novartis as of Q2 2015.

Based on Blue Arrow Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.